Novo Nordisk

California enters a contract to make its own affordable insulin Enlarge this image toggle caption Damian Dovarganes/AP Damian Dovarganes/AP California Gov. Ga...

When Robin Langois, 58, was prescribed the weight-loss drug Wegovy last year, she couldn’t afford the high price tag after her insurance wouldn’t cover it. But...

Drugmaker Sanofi said Thursday that it will cut the list price of its most widely prescribed insulin by 78% and cap out-of-pocket costs for the drug at $35 a mo...

March 17 (Reuters) - Novo Nordisk's diabetes treatment drug Ozempic is back on the shelves after months of shortage, data on the U.S. Food and Drug Administrati...

https://cdn.benzinga.com/files/images/story/2023/03/17/sny.png?optimize=medium&dpr=2&auto=webp&crop=1200%2C800 Sanofi SA (NASDAQ: SNY) jumped the bandwagon wit...

Sanofi will cut the U.S. list price of two of its insulins, making it the third major producer of the diabetes medicine to recently slash prices. French pharma...

Three Is Company - Sanofi Follows Lilly, Novo Nordisk, Slashes Insulin Product Price By 78%...

The biggest U.S. insulin manufacturers have each committed to lower the cost of their products — a move that will save them money by lowering the amount they'd...

[1/2] A pharmacist holds a box of the drug Lantus SoloStar, made by Sanofi Pharmaceutical, at a pharmacy in Provo, Utah, U.S. January 9, 2020. REUTERS/George Fr...

CNN — Sanofi is cutting the list price of Lantus, its most widely prescribed insulin in the US, by 78% and establishing a $35 monthly cap for those with privat...